NCT07216027From ClinicalTrials.govRecruiting

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Atopic Dermatitis
Eczema, Atopic

At a glance

Phase: Phase 2
Study type: Interventional
Sponsor: Pfizer
Enrolment target: 165
Started: 20 November 2025
Main results due: 2 February 2028
Study sites: 33
Registry updated: 25 September 2026

Can you take part?

Ages 18 years to 64 years.
Open to any sex.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Inclusion Criteria:

Participants must meet the following criteria:

1. Are 18 to 64 years of age
2. Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs
3. Have moderate to severe AD as defined by the following at screening and baseline visits:

   * Affected body surface area (BSA) greater than or equal to 10% and up to 60%;
   * Validated Investigator's Global Assessment (vIGA) greater than or equal to 3;
   * Eczema Area and Severity Index (EASI) greater than or equal to 16;

   AND

   -Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit
4. Do not have a suitable prescribed medicine for AD.
5. Body Mass Index (BMI) of 18 to 38 kg/m2 and a total body weight greater than 48 kg (106 lbs)

Exclusion Criteria:

Participants must not meet the following criteria:

1. Have an infection that requires treatment
2. Have other skin conditions other than AD
3. Have severe uncontrolled asthma
4. Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.

The study is seeking participants who:

1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD.

The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.

Study sites(33)

Mayo Clinic Hospital
Phoenix, Arizona, United States
Not yet recruiting
Mayo Clinic Specialty Building
Phoenix, Arizona, United States
Not yet recruiting
Mayo Clinic
Scottsdale, Arizona, United States
Not yet recruiting
Marvel Clinical Research
Huntington Beach, California, United States
Recruiting
Metropolis Dermatology - DTLA
Los Angeles, California, United States
Not yet recruiting
Northridge Clinical Trials
Northridge, California, United States
Recruiting
Clinical Science Institute
Santa Monica, California, United States
Recruiting
Gsi Clinical Research
Margate, Florida, United States
Recruiting
Skin Research of South Florida
Miami, Florida, United States
Active, not recruiting
Montefiore - Jacobi Dermatology Clinic
The Bronx, New York, United States
Recruiting
Montefiore - Clinical Research Center
The Bronx, New York, United States
Recruiting
Montefiore - Greene Medical Arts Pavillion
The Bronx, New York, United States
Recruiting
Montefiore - The Dermatology Center
The Bronx, New York, United States
Recruiting
Montefiore Medical Center
The Bronx, New York, United States
Recruiting
Apex Clinical Research Center, LLC.
Mayfield Heights, Ohio, United States
Not yet recruiting
Paddington Testing Co, Inc
Philadelphia, Pennsylvania, United States
Recruiting
UPMC Department of Dermatology
Pittsburgh, Pennsylvania, United States
Recruiting
Toronto Research Centre
Toronto, Ontario, Canada
Not yet recruiting
Centre de Recherche Saint-Louis inc.
Québec, Canada
Recruiting
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Recruiting
Peking University People's Hospital
Beijing, China
Recruiting
CCR Ostrava, s.r.o.
Ostrava, Czechia
Not yet recruiting
Pratia Czech s.r.o.
Pardubice, Czechia
Not yet recruiting
Hopital Charles Nicolle
Rouen, France
Not yet recruiting
Hopital Larrey
Toulouse, France
Not yet recruiting
Hattori Dermatology Clinic
Takasaki, Gunma, Japan
Recruiting
Kosugi Dermatology Clinic
Kawasaki-shi, Kanagawa, Japan
Recruiting
Queen's square Medical Facilities Queen's square Dermatology and Allergology
Yokohama, Kanagawa, Japan
Recruiting
Dermatology and Ophthalmology Kume Clinic
Sakai, Osaka, Japan
Recruiting
Nihonbashi Sakura Clinic
Chuo-ku, Tokyo, Japan
Recruiting
Fukuwa Clinic
Chuo-ku, Tokyo, Japan
Recruiting
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
Krakow, Lesser Poland Voivodeship, Poland
Not yet recruiting
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, Poland
Not yet recruiting

Showing 33 of 33 sites. 20 of the 33 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07216027. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me